Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Trulieve Cannabis (TCNNF) EBITDA (2020 - 2025)

Trulieve Cannabis (TCNNF) has 6 years of EBITDA data on record, last reported at $15.3 million in Q4 2025.

  • For Q4 2025, EBITDA rose 1069.5% year-over-year to $15.3 million; the TTM value through Dec 2025 reached $143.5 million, up 46.75%, while the annual FY2025 figure was $168.7 million, 40.48% up from the prior year.
  • EBITDA reached $15.3 million in Q4 2025 per TCNNF's latest filing, down from $42.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $83.6 million in Q2 2021 and bottomed at -$291.3 million in Q2 2023.
  • Average EBITDA over 5 years is $15.7 million, with a median of $35.5 million recorded in 2023.
  • Peak YoY movement for EBITDA: crashed 573.07% in 2023, then surged 6734.63% in 2025.
  • A 5-year view of EBITDA shows it stood at -$20.1 million in 2021, then surged by 69.16% to -$6.2 million in 2022, then dropped by 9.98% to -$6.8 million in 2023, then skyrocketed by 119.15% to $1.3 million in 2024, then soared by 1069.5% to $15.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $15.3 million in Q4 2025, $42.2 million in Q3 2025, and $52.6 million in Q2 2025.